-
1
-
-
0024837952
-
The impact of cyclosporine on the practice of renal transplantation
-
Of interest, Useful overview of current clinical experience using CyA in the practice of renal transplantation, emphasizing the fact that allograft rejection continues to be the major problem.
-
(1989)
Transplant Proc
, vol.21
, pp. 63-69
-
-
Kahan1
-
2
-
-
0024419250
-
Prevention Of acute cyclosporin-induced renal blood flow inhibition and improved immunosuppression with verapamil
-
Of interest, A clinical study demonstrating that verapamfl, a calcium channel blocker, diminishes the impairment of renal blood flow induced by CyA with a reduction in nephrotoxicity. Furthermore, a decrease in the incidence of rejection was found in the calcium channel blocker group, probably because of the raised levels of CyA seen in these patients rather than as a direct effect of the calcium channel blocker on the recipient's lymphocyte function. Whether the improved renal function was maintained in the long term was not reported.
-
(1989)
Transplantation
, vol.48
, pp. 575-580
-
-
Dawidson1
Rooth2
Fry3
Sandor4
Willms5
Coorpender6
Alway7
Reisch8
-
3
-
-
0024503989
-
Increased frequency of posttransplant lymphomas in patients treated with cyclosporine, azathioprine, and prednisone
-
Of interest, Confirmation of a clinical impression that immunosuppression with CyA, azathioprine and prednisone (triple therapy) leads to the development of tumours, particularly of the lymphoreticular system.
-
(1989)
Transplantation
, vol.47
, pp. 293-296
-
-
Wilkinson1
Smith2
Hunsicker3
Tobacman4
Kapelanski5
Johnson6
Wright7
Behrendt8
Corry9
-
4
-
-
0024976525
-
Rapamycin for immunosuppression in organ allografting
-
Of interest, First report of the use of rapantycin for immunosuppression in organ allografting in a number of species. Although successful in the rat heart and pig kidney models, this compound produced a severe vasculitis in dogs similar to that seen with FK 506.
-
(1989)
Lancet
, vol.1
, pp. 227
-
-
Calne1
Collier2
Lim3
Pollard4
Samaan5
White6
Thiru7
-
5
-
-
0025322130
-
Toxicologic evaluation of FK 506
-
Of interest, Toxicity study in rats and primates, confirming the earlier findings, particularly in primates, of anorexia, weight loss, lethargy and catatonia together with glycosuria.
-
(1990)
Transplant Pros
, vol.22
, pp. 83-86
-
-
Ohara1
Billington2
James3
Dean4
Nishiyama5
Noguchi6
-
6
-
-
0024419167
-
FK 506 for liver, kidney, and pancreas transplantation
-
Of outstanding interest, First report of the use of FK 506 as ‘salvage’ therapy in allografted patients with uncontrolled rejection or in whom conventional therapy had unacceptable side effects. A remarkable feature is the extremely small dose of FK 506 administered compared with that required to prevent allograft rejection in animal models.
-
(1989)
Lancet
, vol.2
, pp. 1000-1004
-
-
Starzl1
Todo2
Fung3
Demetris4
Venkataramman5
Jain6
-
7
-
-
0025274155
-
Early trials with FK 506 as primary treatment in liver transplantation
-
Of interest, A more detailed description of the first 20 liver transplant patients receiving FK 506. Of these patients, 15 were discharged from hospital within 28 days. A further unusual result was the lack of primary non-function of grafts in patients receiving FK 506.
-
(1990)
Transplant Proc
, vol.22
, pp. 13-16
-
-
Todo1
Funng2
Demetris3
Jain4
Venkataramanan5
Starzl6
-
8
-
-
0025364010
-
Renal transplantation in baboons under FK 506
-
Of interest, Description of the Varying sensitivity of lymphocytes to FK 506 in a range of species. Surprisingly, baboon lymphocytes, as measured by inhibition of the mixed lymphocyte reaction, were 10 times less sensitive to FK 506 than those of rat, dog or man.
-
(1990)
Transplant Proc
, vol.22
, pp. 64-65
-
-
Imventarza1
Todo2
Eiras3
Ueda4
Furukawa5
Wu6
Zhu7
Oks8
Demetris9
Star10
-
11
-
-
0025356121
-
Gastrointestinal ,and metabolic problems associated with immunosuppressan with either CyA or FK 506 in liver transplantation
-
Of interest, Cholesterol levels are raised by CyA because of the enhanced production of cholesterol as a result of up-regulation of the rate-limiting enzyme involved in cholesterol biosynthesis. Upon transfer from CyA to FK 506, cholesterol levels returned to normal.
-
(1990)
Transplant Proc
, vol.22
, pp. 37-40
-
-
Van Theil1
Iqbal2
Jain3
Fund4
Todo5
Starzl6
-
12
-
-
0024554052
-
Synergistically enhanced immunosuppressane effect by combined use of cyclosporine and mizorlbine
-
Of interest, An experimental and clinical study reporting that a combination of CyA and mizoribine is effective in preventing allograft rejection with a 90% 1-year graft survival rate in cadaveric renal transplants. The control groups, which received either azathioprine and prednisone or CyA alone, have rather lower graft survival rates than would be expected.
-
(1990)
Transplant Proc
, vol.21
, pp. 956-958
-
-
Amemiya1
Suzuki2
Watanabe3
Hayashi4
Niiya5
-
14
-
-
84909727692
-
-
Describes a guanosine monophosphate synthesis inhibitor that, when combined with CyA and prednisone, was effective in preventing allograft rejection in dogs although when given at high doses alone it produced significant weight loss in the animals. Clinical trials are ongoing.
-
-
-
-
15
-
-
0025220079
-
A novel rescue drug, 15-Deoxyspergualin. First clinical trials for recurrent graft rejection in renal recipients
-
Of interest, Early clinical trial of DSG in the treatment of acute rejection with a success rate of more than 80% including cases of steroid-resistant rejection. However; only a limited number of patients were entered into the trial.
-
(1989)
Transplantation
, vol.49
, pp. 337-343
-
-
Amemiya1
Suzuki2
Ota3
Takahasm4
Sonoda5
Ishibashi6
Omoto7
Koyama8
Dohi9
Fukuda10
Fukao11
-
17
-
-
0024832246
-
Treatment of cyclosporin-induced haemolytic umemic syndrome with FK 506
-
Of interest, A letter reporting one case in which transfer from CyA to FK 506 resolved CyA-induced haemolytic uraemic syndrome whilst maintaning immunosuppression.
-
(1989)
Lancet
, vol.2
, pp. 1516
-
-
McCauley1
Bronsther2
Fung3
Todo4
Stam5
-
18
-
-
0025266450
-
FK 506 in steroid-resistant focal sclerosing glomerulonephritis of childhood
-
Of interest, Two case reports describing the effectiveness of FK 506 in resolving focal sclerosing glomerulonephritis that had failed to respond to steroid therapy.
-
(1990)
Lancet
, vol.1
, pp. 674
-
-
McCauley1
Tzakis2
Fung3
Todo4
Starzl5
-
19
-
-
0024548313
-
Contingent genetic regulatory events in T lymphocyte activation
-
Of interest, An excellent review of the mechanisms leading to T-lymphocyte activation following their encounter with foreign antigens and possible sites of action of CyA.
-
(1989)
Science
, vol.243
, pp. 355-361
-
-
Crabtree1
-
20
-
-
0024959449
-
Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins
-
Of outstanding interest, Peptidyl-prolyl cis-trans isomerase (PPIase) acts on proline imidic peptide bonds, accelerating protein folding; the chemical and enzymatic properties of a PPLase extracted from pig kidney indicate that this enzyme is identical to cyclophilin and that its activity is inhibited by CyA.
-
(1989)
Nature
, vol.337
, pp. 476-478
-
-
Fisher1
Wittmann-Lieboid2
Lang3
Kiefhaber4
Schmd5
-
21
-
-
0024442393
-
A cytosolic binding protein for the immunosuppressant FK 506 has ireptidfi-protyl isomerase activity but is distinct from cyclophilin
-
Of outstanding interest, Specific cytosolic binding proteins for CyA (cyclophilin) and FK 506 (fujiphilin) both have PPIase activity, which is specifically inhibited by the appropriate immunosuppressane agent.
-
(1989)
Nature
, vol.341
, pp. 755-757
-
-
Sieiuerka1
Hung2
Poe3
Lin4
Sigal5
-
22
-
-
0024412228
-
The immunosuppressant FK506 selectivity inhibits expression of early T cell activation genes
-
Of outstanding interest, FK 506, like CyA, acts by preventing induction of the early genes following T-cell activation, in particular the gene for IL-2. Rapamycin, although structurally similar to FK 506, does not act by this mechanism but at a later stage of T-cell activation.
-
(1989)
J Immunol
, vol.143
, pp. 718-725
-
-
Tocci1
Matkovich2
Collier3
Kwok4
Dumont5
Lin6
Degudicibus7
Siekierka8
Chin9
Hutcrwson10
-
23
-
-
0024588302
-
Macrophages as targets for inhibition by cyclosporine
-
Of interest, CyA, as well as interfering with T-cell function, also affects the alloreactive process at an earlier stage by modifying the function of macrophages, as antigen-presenting cells.
-
(1989)
Transplantation
, vol.47
, pp. 696-703
-
-
Benson1
Ziegier2
-
24
-
-
0025237793
-
The immunosuppressane action of FK506. In vitro induction of allogencic unresponsiveness in human CTL precursors
-
Of interest, FK 506 also appears to have an effect at the early stage of the immune response by modifying antigen presentation in vitro before the alloreactive response by T lymphocytes; whether this is significant for either CyA or FK 506 in vivo is unknown.
-
(1990)
Transplantation
, vol.49
, pp. 390-396
-
-
Thomas1
Matthews2
Carroll3
Loreth4
Thomas5
-
25
-
-
0024847763
-
The effects of Deoxyspergualin on lymphocytes and monocytes in vivo and in vitro
-
Of interest, DSG was thought to act primarily by affecting macrophage antigen-presenting cell function. This work indicates that it may have an effect on lymphocytes at a later stage of their response, after the presentation of foreign antigen by antigen-presenting cells.
-
(1989)
Transplantation
, vol.48
, pp. 1048-1052
-
-
Kerr1
Atkins2
|
